Skip to content
Bored Studies
RecruitingPhase 2

Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis

AbbVie · NCT06865105

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
120
US sites recruiting
15
Study start
April 11, 2025
Record last updated
December 18, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms.

The therapies being assessed in this sub-study are risankizumab and lutikizumab. Participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: lutikizumab monotherapy, risankizumab monotherapy or a combination therapy of lutikizumab and risankizumab. Around 120 participants will be enrolled in the study at approximately 40 sites worldwide.

There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Being studied: Lutikizumab; Risankizumab

Conditions: Psoriatic Arthritis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Participant is willing and able to comply with procedures required in the Master Protocol and substudies.
  • Participant has a documented clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) at Screening Visit.
  • Participant has active disease defined as greater than or equal to 3 tender joints (based on 68 joint count) and greater than or equal to 3 swollen joints (based on 66 joint count) at both the Screening Visit and Baseline.
  • Participant has active plaque PsO and/or a documented history of plaque PsO.
  • Participant must demonstrate intolerance or inadequate response to 1 to 2 targeted therapies (biologic or targeted synthetic disease-modifying antirheumatic drugs) approved for the treatment of PsA

Exclusion Criteria

  • Participants who have had major surgery performed within 12 weeks prior to randomization or plan to have a major surgery during conduct of the study (e.g., aneurysm removal, stomach ligation).
  • Participants with the following chronic or active infections: Are infected with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus(HCV) infection, active tuberculosis(TB)
  • Active skin disease other than psoriasis (PsO) which could interfere with the assessment of PsO.
  • History of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than psoriatic arthritis (PsA) (including but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus).

Recruiting US locations

  • Newport Huntington Medical Group /ID# 272764

    Huntington Beach, CA 92648-5994

    Site contact: Site Coordinator · 714-923-7112

  • Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 273085

    Avon Park, FL 33825

    Site contact: Site Coordinator · 863-314-8555

  • Clinical Research Of West Florida - Phase I Unit /ID# 273198

    Clearwater, FL 33765

  • HMD Research LLC /ID# 273086

    Orlando, FL 32819

  • West Broward Rheumatology Associates /ID# 272892

    Tamarac, FL 33321

  • Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 273199

    Tampa, FL 33606

    Site contact: Site Coordinator · (813) 870-1292

  • Clinic Of Dr. Robert Hozman/Clinical Investigation Specialists, Inc /ID# 272879

    Skokie, IL 60076

    Site contact: Site Coordinator · 847-599-2492

  • Willow Rheumatology and Wellness, PLLC /ID# 277354

    Willowbrook, IL 60527

  • Paramount Medical Research and Consulting /ID# 272757

    Middleburg Heights, OH 44130

  • Altoona Center For Clinical Research /ID# 272593

    Duncansville, PA 16635

    Site contact: Site Coordinator · 814-296-6108

  • Private Practice - Dr. Ramesh C. Gupta I /ID# 272897

    Memphis, TN 38119

  • Tekton Research - West Gate /ID# 272765

    Austin, TX 78745

  • Accurate Clinical Research - Houston /ID# 272754

    Houston, TX 77089-6142

    Site contact: Site Coordinator · 281-481-8557

  • Tekton Research, LLC /ID# 272901

    San Antonio, TX 78251

  • Dynamed Clinical Research - Tomball /ID# 272760

    Tomball, TX 77375

Study contacts (from the official record)

  • ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
All dermatology studies in California →
Study of Targeted Therapies for the Treatment of Adult… (NCT06865105) | Bored Studies